Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +47.86%
#3 Velvet Velvet +43.20%
#4 Akedo Akedo +42.96%
#5 Black Phoenix Black Phoenix +34.22%
#6 Cross Cross +21.95%
#7 DoubleZero DoubleZero +17.10%
#8 Cap Cap +16.75%
#9 Tutorial Tutorial +15.51%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.76%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Kedudukan dalam Saham #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Harga Saham
$0.11725176
Disegerakkan terakhir: 2025-07-14
Modal Pasaran
$481.50K
Perubahan (1 hari)
-0.20%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan PHAXIAM Therapeutics S.A. (PHXM)

Kategori

Healthcare
Pendapatan untuk PHAXIAM Therapeutics S.A. (PHXM)
Pendapatan pada Jun 2024 TTM: $-23.51M
Menurut laporan kewangan terkini PHAXIAM Therapeutics S.A., pendapatan semasa syarikat ialah $-23.51M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-1.28M, peningkatan berbanding pendapatan pada tahun 2021 yang berjumlah $-65.34M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi PHAXIAM Therapeutics S.A. dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-23.51M -14.00%
2023 $-27.34M 2,036.64%
2022 $-1.28M -98.04%
2021 $-65.34M -30.07%
2020 $-93.44M 25.10%
2019 $-74.70M 52.60%
2018 $-48.95M 11.10%
2017 $-44.06M 64.85%
2016 $-26.73M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -22,533.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -8,395.72%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -12,882.70%
BE